Mohammed Alrouji

1.2k total citations
58 papers, 720 citations indexed

About

Mohammed Alrouji is a scholar working on Molecular Biology, Pharmacology and Computational Theory and Mathematics. According to data from OpenAlex, Mohammed Alrouji has authored 58 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Pharmacology and 10 papers in Computational Theory and Mathematics. Recurrent topics in Mohammed Alrouji's work include Computational Drug Discovery Methods (10 papers), Cholinesterase and Neurodegenerative Diseases (9 papers) and Alzheimer's disease research and treatments (7 papers). Mohammed Alrouji is often cited by papers focused on Computational Drug Discovery Methods (10 papers), Cholinesterase and Neurodegenerative Diseases (9 papers) and Alzheimer's disease research and treatments (7 papers). Mohammed Alrouji collaborates with scholars based in Saudi Arabia, United Arab Emirates and Egypt. Mohammed Alrouji's co-authors include Ali I. Al‐Gareeb, Gaber El‐Saber Batiha, Hayder M. Al‐kuraishy, ‏Hebatallah M. Saad, Αθανάσιος Αλεξίου, Anas Shamsi, Marios Papadakis, Cris S. Constantinescu, Bruno Gran and Majid S. Jabir and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Mohammed Alrouji

54 papers receiving 716 citations

Peers

Countries citing papers authored by Mohammed Alrouji

Since Specialization

Citations

This map shows the geographic impact of Mohammed Alrouji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed Alrouji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed Alrouji more than expected).

Fields of papers citing papers by Mohammed Alrouji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed Alrouji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed Alrouji. The network helps show where Mohammed Alrouji may publish in the future.

Co-authorship network of co-authors of Mohammed Alrouji

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed Alrouji. A scholar is included among the top collaborators of Mohammed Alrouji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed Alrouji. Mohammed Alrouji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive spectroscopic and computational insight into the binding of vanillin with human transferrin: targeting neuroinflammation in Alzheimer’s disease therapeutics 2024 ·Frontiers in Pharmacology ·Mohammed Alrouji, Sabina Yasmin, Fahad A. Alhumaydhi, (unknown), (unknown), (unknown), (unknown), Anas Shamsi	2
2	Role of Autophagy in Type 2 Diabetes Mellitus: The Metabolic Clash 2024 ·Journal of Cellular and Molecular Medicine ·(unknown), (unknown), Ali I. Al‐Gareeb, Αθανάσιος Αλεξίου, Marios Papadakis, (unknown), Walaa A. Negm, (unknown), Mohammed Alrouji, Gaber El‐Saber Batiha	2
3	Unveiling the Molecular Interactions Between Human Transferrin and Limonene: Natural Compounds in Alzheimer’s Disease Therapeutics 2024 ·Journal of Alzheimer s Disease ·Mohammed Alrouji, Sabina Yasmin, Mohammad Furkan, Fahad A. Alhumaydhi, (unknown), Rizwan Hasan Khan, Anas Shamsi	4
4	Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon 2024 ·Cellular and Molecular Neurobiology ·(unknown), Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Najah R. Hadi, (unknown), Mohammed Alrouji, Nermeen N. Welson, Αθανάσιος Αλεξίου, Marios Papadakis, Gaber El‐Saber Batiha	6
5	Molecular Signaling Pathways of Quercetin in Alzheimer’s Disease: A Promising Arena 2024 ·Cellular and Molecular Neurobiology ·Mansour Alsaleem, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Ali K. Albuhadily, Mohammed Alrouji, (unknown), Αθανάσιος Αλεξίου, Marios Papadakis, Gaber El‐Saber Batiha	2
6	Repurposed drugs as histone deacetylase 8 inhibitors: Implications in cancer and neuropathological conditions 2024 ·Frontiers in Pharmacology ·Mohammed Alrouji, Kumar Venkatesan, (unknown), Fahad A. Alhumaydhi, (unknown), (unknown), Moyad Shahwan, Anas Shamsi	0
7	Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspective 2024 ·Neuropsychopharmacology Reports ·Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, (unknown), Αθανάσιος Αλεξίου, Marios Papadakis, (unknown), Gaber El‐Saber Batiha	23
8	Iron homeostasis and neurodegeneration in the ageing brain: Insight into ferroptosis pathways 2024 ·Ageing Research Reviews ·Mohammed Alrouji, Saleha Anwar, Kumar Venkatesan, Moyad Shahwan, Md. Imtaiyaz Hassan, Asimul Islam, Anas Shamsi	15
9	Assessment of the anti-cancer potential of Ephedra foeminea leaf extract on MDA-MB-231, MCF-7, 4 T1, and MCF-10 breast cancer cell lines: Cytotoxic, apoptotic and oxidative assays 2024 ·Saudi Pharmaceutical Journal ·(unknown), (unknown), Mohammed Asad, Mohammed Alrouji, (unknown), (unknown)	4
10	The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer’s diseases 2023 ·Diabetology & Metabolic Syndrome ·Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Αθανάσιος Αλεξίου, Marios Papadakis, ‏Hebatallah M. Saad, Gaber El‐Saber Batiha	47
11	Hypolipidemic and Antihyperlipidemic Effects of Holarrhena pubescens Methanolic Extract Is Mediated through Inhibition of Lipase Activity and Lipid Accumulation 2023 ·Life ·(unknown), Mohammed Asad, Mohammed Alrouji, (unknown), (unknown), (unknown)	1
12	Immunological interactions in helminths‐SARS CoV ‐2 coinfection: Could old enemy be a friend today? 2023 ·Parasite Immunology ·Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, (unknown), Αθανάσιος Αλεξίου, Marios Papadakis, Hanan A. Ogaly, Ahmed M. El‐Gazzar, Gaber El‐Saber Batiha	5
13	Secondary Metabolite Profiling, Antioxidant, Antidiabetic and Neuroprotective Activity of Cestrum nocturnum (Night Scented-Jasmine): Use of In Vitro and In Silico Approach in Determining the Potential Bioactive Compound 2023 ·Plants ·Saheem Ahmad, Mohammed Alrouji, (unknown), (unknown), Ramendra Pati Pandey, Mohammad Saquib Ashraf, Shafeeque Ahmad, Saif Khan	8
14	Insight into the Biological Roles and Mechanisms of Phytochemicals in Different Types of Cancer: Targeting Cancer Therapeutics 2023 ·Nutrients ·Taghreed A. Majrashi, Saad Ali Alshehri, Abdulrhman Alsayari, Abdullatif Bin Muhsinah, Mohammed Alrouji, Asma M. Alshahrani, Anas Shamsi, Akhtar Atiya	40
15	Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders Using In Silico and In Vitro Approaches 2023 ·ACS Omega ·Akhtar Atiya, (unknown), Abdulrhman Alsayari, Mohammed Alrouji, (unknown), (unknown), Waleed Al Abdulmonem, Nasser M. Alorfi, K.M. Abdullah, Anas Shamsi	16
16	Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies 2023 ·Scientific Reports ·Mohammed Alrouji, (unknown), Fahad A. Alhumaydhi, Waleed Al Abdulmonem, Saleh Baeesa, Mohd Rehan, Moyad Shahwan, Anas Shamsi, Akhtar Atiya	5
17	Orexin pathway in Parkinson’s disease: a review 2023 ·Molecular Biology Reports ·Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Dalia Zaafar, Gaber El‐Saber Batiha	22
18	DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson’s disease: a mutual relationship 2023 ·Pharmacological Reports ·Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali K. Albuhadily, Ali I. Al‐Gareeb, Engy Elekhnawy, Gaber El‐Saber Batiha	29
19	Pimitespib, an HSP90 inhibitor, augments nifuroxazide-induced disruption in the IL-6/STAT3/HIF-1α autocrine loop in rats with bleomycin-challenged lungs: Evolutionary perspective in managing pulmonary fibrosis 2022 ·Biomedicine & Pharmacotherapy ·Dalia H. El‐Kashef, Mahmoud E. Youssef, (unknown), Mohammed Alrouji, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Osama A. Mohammed, Nesreen Elsayed Morsy, Ahmed Shata, Sameh Saber	16
20	Increased IL-2 and Reduced TGF-β Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis 2020 ·Biomedicines ·Jehan Aram, Nanci Frakich, Elena Morandi, Mohammed Alrouji, Amal Samaraweera, David Onion, Ian Spendlove, Sergio L. Colombo, Radu Tănăsescu, Bruno Gran, Cris S. Constantinescu	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact